Amneal Pharmaceuticals, Inc. Class A Aktie News

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2024 Results on May 3, 2024.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Ring the Nasdaq Closing Bell on April 2, 2024.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension.

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2023. “Amneal had a very successful year in 2023 as we delivered strong execution and growth across our diversified pharmaceutical business. We are starting 2024 with substantial momentum and key catalysts...

BRIDGEWATER, N.J. & CADEMPINO, Switzerland--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland. IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference. Barclays 26th Annual Global Healthcare Conference March 13, 2024 Miami, FL Fireside chat – 8:30 AM ET One-on-one meetings to follow A live webcast of the presentation will be accessible through the I...